Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 4/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.38 |
| ▸ | CDK2 | P24941 | 2/20 | 0.38 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.38 |
| ▸ | IDH1 | O75874 | 8/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5449357 | 0.90 | HRH4 (0.41) | HRH4F2MAPTKMT2AIDH1 | |
| SCHEMBL5454692 | 0.86 | HRH4 (0.39) | HRH4F2MAPTKMT2ACCNA2 | |
| SCHEMBL5456511 | 0.84 | CCNA2 (0.56) | HRH4CCNA2CDK2CCNA1 | |
| SCHEMBL5447010 | 0.82 | KMT2A (0.39) | F2MAPTKMT2AIDO1KCNH2 | |
| SCHEMBL5459485 | 0.82 | IDH1 (0.43) | KMT2AIDH1RAB9ASMN1; SMN2 | |
| SCHEMBL5453832 | 0.80 | ALDH1A1 (0.43) | CCNA2CDK2CCNA1ALDH1A1 | |
| SCHEMBL5453843 | 0.80 | RAB9A (0.46) | MAPTCDK2RAB9ASMN1; SMN2 | |
| SCHEMBL5451959 | 0.78 | CDK2 (0.43) | CCNA2CDK2CCNA1ALDH1A1SMN1; SMN2 | |
| SCHEMBL5452844 | 0.77 | HTR1F (0.43) | CCNA2CDK2CCNA1 | |
| SCHEMBL5454247 | 0.77 | F2 (0.39) | HRH4F2KMT2ACDK2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070037790-A1 | Bicyclo-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2007-02-15 | — | — | US | claimed |
| US-20070037790-A1 | Bicyclo-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037790-A1 | Bicyclo-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | MAP3K15, MAP3K7, MAP3K19 | HRH4 3846/4885F2 4351/4885MAPT 217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.